JAQUELINE RIBEIRO SCHOLZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
- Position Statement on Women's Cardiovascular Health-2022(2022) OLIVEIRA, Glaucia Maria Moraes de; ALMEIDA, Maria Cristina Costa de; MARQUES-SANTOS, Celi; COSTA, Maria Elizabeth Navegantes Caetano; CARVALHO, Regina Coeli Marques de; FREIRE, Claudia Maria Vilas; MAGALHAES, Lucelia Batista Neves Cunha; HAJJAR, Ludhmila Abrahao; RIVERA, Maria Alayde Mendonca; CASTRO, Marildes Luiza de; AVILA, Walkiria Samuel; LUCENA, Alexandre Jorge Gomes de; BRANDAO, Andrea Araujo; MACEDO, Ariane Vieira Scarlatelli; LANTIERI, Carla Janice Baister; POLANCZYK, Carisi Anne; ALBUQUERQUE, Carlos Japhet da Matta; BORN, Daniel; FALCHETO, Eduardo Belisario; BRAGANCA, Erika Olivier Vilela; BRAGA, Fabiana Goulart Marcondes; COLOMBO, Fernanda M. Consolim; JATENE, Ieda Biscegli; COSTA, Isabela Bispo Santos da Silva; RIVERA, Ivan Romero; SCHOLZ, Jaqueline Ribeiro; MELO FILHO, Jose Xavier de; SANTOS, Magaly Arrais dos; BARBOSA, Marcia de Melo; IZAR, Maria Cristina de Oliveira; AZEVEDO, Maria Fatima; MOURA, Maria Sanali; CAMPOS, Milena dos Santos Barros; SOUZA, Olga Ferreira de; MEDEIROS, Orlando Otavio de; SILVA, Sheyla Cristina Tonheiro Ferro da; RIZK, Stephanie Itala; RODRIGUES, Thais de Carvalho Vieira; SALIM, Thais Rocha; LEMKE, Viviana de Mello Guzzo; ALEXANDRE, Elisabeth Regina Giunco
- Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting(2016) SILVA, Andre Pacheco; SCHOLZ, Jaqueline; ABE, Tania Ogawa; PINHEIRO, Gabriela Gouveia; GAYA, Patricia Viviane; PEREIRA, Alexandre Costa; SANTOS, Paulo Caleb Junior LimaBackground: Smoking is the most important reversible cardiovascular risk factor. It is well established that quitting smoking reduces coronary events. However, on several occasions, the cardiovascular safety of smoking cessation drugs has been questioned. Our goal is to evaluate the effects of smoking cessation drugs on blood pressure and heart rate in patients from a smoking cessation service in a cardiology hospital. Methods: We examined the PAF database (Smoking Cessation Assistance Program database) between January 2008 and March 2014. We analyzed data from 900 patients who were compliant with the treatment (50.5 % male, average age 53 +/- 17 years). The most frequent clinical diagnoses were coronary artery disease (25.2 %), hypertension (57.2 %), and diabetes (13.4 %). Blood pressure, heart rate, and carbon monoxide (CO) concentration in exhaled air were analyzed at consecutive visits during the first 45 days of treatment (mean visits - 3). Analysis of repeated measures was used for the statistical analysis (p < 0.05). Results: Two hundred seventy one patients used nicotine replacement therapy (NRT) alone, 81 used bupropion alone, 154 used varenicline alone, 283 used NRT plus bupropion and 111 used bupropion plus varenicline. For all smoking cessation drugs, used alone or in combination, no increase occurred in the average value of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Significant reductions in CO concentrations occurred in all smoking cessation drug groups. Conclusion: Smoking cessation drugs used in monotherapy or in combined regimens did not influence systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in this group of patients during the observation period.
- Could be applied genetic markers to smoking cessation treatment?(2018) GAYA, P. V.; SCHOLZ, J.; SANTOS, J. R. dos; TOMAZ, P. R. X.; ABE, T. M. O.; NASSIF JUNIOR, M.; PEREIRA, A. C.; SANTOS JUNIOR, P. C. dos
- Comparison of RNA Extraction Methods for Molecular Analysis of Oral Cytology(2016) ALVES, Monica Ghislaine Oliveira; PEREZ-SAYANS, Mario; PADIN-IRUEGAS, Maria-Elena; REBOIRAS-LOPEZ, Maria Dolores; SUAREZ-PENARANDA, Jose Manuel; LOPEZ-LOPEZ, Rafael; CARTA, Celina Faig Lima; ISSA, Jaqueline Scholz; GARCIA-GARCIA, Abel; ALMEIDA, Janete DiasObjective of work: The aim of this study was to compare three methods of RNA extraction for molecular analysis of oral cytology to establish the best technique, considering its concentration and purity for molecular tests of oral lesions such as real-time reverse transcriptase reaction. Material and methods: The sample included exfoliative cytology from the oral cavity mucosa of patients with no visible clinical changes, using Orcellex Rovers Brush (R). The extraction of total RNA was performed using the following three techniques: 30 samples were extracted by Trizol (R) technique, 30 by the Directzol (TM) RNA Miniprep system and 30 by the RNeasy mini Kit. The absorbance was measured by spectrophotometer to estimate the purity. The estimated RNA concentration was obtained by multiplying the value of A260 (ng/mL) by 40. Statistical analysis of the obtained data was performed using GraphPad Prism 5.03 software with Student t, analysis of variance and Bonferroni tests, considering p <= 0.05. Results: Trizol (R) group revealed higher average concentration, followed by Direct-zol (TM) and Rneasy group. It was observed that the RNA Direct-zol (TM) group had the highest purity, followed by RNeasy and Trizol (R) groups, allowing for the two ratios. Conclusion: Considering all aspects, concentration, purity and time spent in the procedures, the Direct-zol (TM) group showed the best results.
- Um novo escore para dependência a nicotina e uma nova escala de conforto do paciente durante o tratamento do tabagismo(2012) ISSA, Jaqueline ScholzSmoking is considered the leading preventable cause of morbidity and mortality. The pharmacological management of nicotine withdrawal syndrome enables better cessation rates. In our smoking cessation program, we have developed a data collection system, which includes two new instruments: a score that assesses nicotine dependence in smokers of <= 10 cigarettes/day; and a patient comfort scale to be used during smoking cessation treatment. Here, we describe the two instruments, both of which are still undergoing validation.
- CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy(2015) SANTOS, Juliana Rocha; TOMAZ, Paulo R. X.; ISSA, Jaqueline S.; ABE, Tania O.; KRIEGER, Jose E.; PEREIRA, Alexandre C.; SANTOS, Paulo C. J. L.Background: The large individual variability in response to drugs for smoking cessation suggests that specific treatments can be more effective in particular subgroups of smokers. In the context of personalized medicine, the main aim of the present study was to evaluate whether the CHRNA4 and CHRNB2 polymorphisms are associated with response to smoking cessation therapies in patients from a smoker assistance program. Methods: This cohort study enrolled 483 smoking patients who received behavioral counseling and drug treatment (varenicline, bupropion, and/or nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerstrom test for nicotine dependence (FTND) and lssa situational smoking scores were analyzed for nicotine dependence. The CHRNA4 (rs1044396 and rs2236196) and CHRNB2 (rs2072660 and rs2072661) polymorphisms were genotyped by high resolution melting analysis. Results: Patients with rs1044396 CC genotype had lower success rate in treatment with varenicline (29.5%) compared with carriers of CT or TT genotypes (50.9%; p = 0.007, n = 167). The CT or TT genotypes were associated with higher odds ratio for success (OR = 1.67, 95% CI = 1.10-2.53, p = 0.02), in a multivariate model. We did not observe significant differences in the FTND and lssa scores according to the studied polymorphisms. Conclusion: The CHRNA4 rs1044396 is associated with smoking cessation in individuals on varenicline therapy. We suggest that this polymorphism influences the varenicline response, but replications of this finding are needed.
- Surgery is unlikely to be enough for a patient to stop smoking 24 h prior to hospital admission(2018) MARINHO, Igor Maia; CARMONA, Maria Jose C.; BENSENOR, Fabio Ely Martins; HERTEL, Julia Mintz; MORAES, Marcos Fernando Breda de; SANTOS, Paulo Caleb Junior Lima; VANE, Matheus Fachini; ISSA, Jaqueline ScholzIntroduction: The need for surgery can be a decisive factor for long-term smoking cessation. On the other hand, situations that precipitate stress could precipitate smoking relapse. The authors decided to study the impact of a surgery on the patient's effort to cease smoking for, at least, 24 h before hospital admission and possible relapse on the last 24 h before hospital admission for ex-smokers. Methods: Smoker, ex-smokers and non-smokers adults, either from pre-anesthetic clinic or recently hospital admitted for scheduled elective surgeries that were, at most, 6 h inside the hospital buildings were included in the study. The patients answered a questionnaire at the ward or at the entrance of the operating room (Admitted group) or at the beginning of the first pre-anesthetic consultation (Clinic group) and performed CO measurements. Results: 241 patients were included, being 52 ex-smokers and 109 never smokers and 80 non-smokers. Smokers had higher levels of expired carbon monoxide than non-smokers and ex-smokers (9.97 +/- 6.50 vs. 2.26 +/- 1.65 vs. 2.98 +/- 2.69; p= 0.02). Among the smokers, the Clinic group had CO levels not statistically different of those on the Admitted group (10.93 +/- 7.5 vs. 8.65 +/- 4.56; p= 0.21). The ex-smokers presented with no significant differences for the carbon monoxide levels between the Clinic and Admitted groups (2.9 +/- 2.3 vs. 2.82 +/- 2.15; p= 0.45). Conclusion: A medical condition, such as a surgery, without proper assistance is unlikely to be enough for a patient to stop smoking for, at least, 24 h prior to admission. The proximity of a surgery was not associated with smoking relapse 24 h before the procedure. (C) 2018 Sociedade Brasileira de Anestesiologia.
- Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017(2017) FALUDI, A. A.; IZAR, M. C. O.; SARAIVA, J. F. K.; CHACRA, A. P. M.; BIANCO, H. T.; AFIUNE NETO, A.; BERTOLAMI, A.; PEREIRA, A. C.; LOTTENBERG, A. M.; SPOSITO, A. C.; CHAGAS, A. C. P.; CASELLA-FILHO, A.; SIMAO, A. F.; ALENCAR FILHO, A. C.; CARAMELLI, B.; MAGALHAES, C. C.; MAGNONI, D.; NEGRAO, C. E.; FERREIRA, C. E. S.; SCHERR, C.; FEIO, C. M. A.; KOVACS, C.; ARAUJO, D. B.; CALDERARO, D.; GUALANDRO, D. M.; MELLO JUNIOR, E. P.; ALEXANDRE, E. R. G.; SATO, I. E.; MORIGUCHI, E. H.; RACHED, F. H.; SANTOS, F. C.; CESENA, F. H. Y.; FONSECA, F. A. H.; FONSECA, H. A. R.; XAVIER, H. T.; PIMENTEL, I. C.; GIULIANO, I. C. B.; ISSA, J. S.; DIAMENT, J.; PESQUERO, J. B.; SANTOS, J. E.; FARIA NETO, J. R.; MELO FILHO, J. X.; KATO, J. T.; TORRES, K. P.; BERTOLAMI, M. C.; V, M. H. Assad; MINAME, M. H.; SCARTEZINI, M.; FORTI, N. A.; COELHO, O. R.; MARANHAO, R. C.; SANTOS FILHO, R. D.; ALVES, R. J.; CASSANI, R. L.; BETTI, R. T. B.; CARVALHO, T.; MARTINEZ, T. L. R.; GIRALDEZ, V. Z. R.; SALGADO FILHO, W.
- Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology-2019(2019) PRECOMA, Dalton Bertolim; OLIVEIRA, Glaucia Maria Moraes de; SIMAO, Antonio Felipe; DUTRA, Oscar Pereira; COELHO, Otavio Rizzi; IZAR, Maria Cristina de Oliveira; POVOA, Rui Manuel dos Santos; GIULIANO, Isabela de Carlos Back; ALENCAR FILHO, Aristoteles Comte de; MACHADO, Carlos Alberto; SCHERR, Carlos; FONSECA, Francisco Antonio Helfenstein; SANTOS FILHO, Raul Dias dos; CARVALHO, Tales de; JR, Alvaro Avezum; ESPORCATTE, Roberto; NASCIMENTO, Bruno Ramos; BRASIL, David de Padua; SOARES, Gabriel Porto; VILLELA, Paolo Blanco; FERREIRA, Roberto Muniz; MARTINS, Wolney de Andrade; SPOSITO, Andrei C.; HALPERN, Bruno; SARAIVA, Jose Francisco Kerr; CARVALHO, Luiz Sergio Fernandes; TAMBASCIA, Marcos Antonio; COELHO-FILHO, Otavio Rizzi; BERTOLAMI, Adriana; CORREA FILHO, Harry; XAVIER, Hermes Toros; FARIA-NETO, Jose Rocha; BERTOLAMI, Marcelo Chiara; GIRALDEZ, Viviane Zorzanelli Rocha; BRANDAO, Andrea Araujo; FEITOSA, Audes Diogenes de Magalhaes; AMODEO, Celso; SOUZA, Dilma do Socorro Moraes de; BARBOSA, Eduardo Costa Duarte; MALACHIAS, Marcus Vinicius Bolivar; SOUZA, Weimar Kunz Sebba Barroso de; COSTA, Fernando Augusto Alves da; RIVERA, Ivan Romero; PELLANDA, Lucia Campos; SILVA, Maria Alayde Mendonca da; ACHUTTI, Aloyzio Cechella; LANGOWISKI, Andre Ribeiro; LANTIERI, Carla Janice Baister; SCHOLZ, Jaqueline Ribeiro; ISMAEL, Silvia Maria Cury; AYOUB, Jose Carlos Aidar; SCALA, Luiz Cesar Nazario; NEVES, Mario Fritsch; JARDIM, Paulo Cesar Brandao Veiga; FUCHS, Sandra Cristina Pereira Costa; JARDIM, Thiago de Souza Veiga; MORIGUCHI, Emilio Hideyuki; SCHNEIDER, Jamil Cherem; ASSAD, Marcelo Heitor Vieira; KAISER, Sergio Emanuel; LOTTENBERG, Ana Maria; MAGNONI, Carlos Daniel; MINAME, Marcio Hiroshi; LARA, Roberta Soares; HERDY, Artur Haddad; ARAUJO, Claudio Gil Soares de; MILANI, Mauricio; SILVA, Miguel Morita Fernandes da; STEIN, Ricardo; LUCCHESE, Fernando Antonio; NOBRE, Fernando; GRIZ, Hermilo Borba; MAGALHAES, Lucelia Batista Neves Cunha; BORBA, Mario Henrique Elesbao de; PONTES, Mauro Ricardo Nunes; MOURILHE-ROCHA, Ricardo
- Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women(2018) TOMAZ, Paulo Roberto Xavier; SANTOS, Juliana Rocha; SCHOLZ, Jaqueline; ABE, Tania Ogawa; GAYA, Patricia Viviane; NEGRAO, Andre Brooking; KRIEGER, Jose Eduardo; PEREIRA, Alexandre Costa; SANTOS, Paulo Caleb Junior LimaBackground: The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated with smoking phenotypes are increasingly important for prevention and treatment of nicotine dependence. In the context of personalized medicine, the aims of this study were to evaluate whether cholinergic receptor nicotinic alpha 2 (CHRNA2), cholinergic receptor nicotinic alpha 3 (CHRNA3), cholinergic receptor nicotinic alpha 5 (CHRNA5) and cholinergic receptor nicotinic beta 3 (CHRNB3) polymorphisms were associated with nicotine dependence severity, and to investigate possible pharmacogenetics markers of smoking cessation treatment. Methods: This study cohort enrolled 1049 smoking patients who received pharmacological treatment (varenicline, varenicline plus bupropion, bupropion plus/or nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerstrom test for nicotine dependence (FTND) and Issa situational smoking scores (Issa score) were analyzed for nicotine dependence. CHRNA2 (rs2472553), CHRNA3 (rs1051730), CHRNA5 (rs16969968 and rs2036527) and CHRNB3 (rs6474413) polymorphisms were genotyped by high resolution melting analysis. Results: Females with GA and AA genotypes for CHRNA5 rs16969968 and rs2036527 polymorphisms had higher success rate in smoking cessation treatment: 44.0% and 56.3% (rs16969968), 41.5% and 56.5% (rs2036527), respectively, compared with carriers of the GG genotypes: 35.7% (rs16969968), 34.8% (rs2036527), (P = 0.03, n = 389; P = 0.01, n = 391). The GA or AA genotypes for the rs16969968 and rs2036527 were associated with higher odds ratio for success in women (OR = 1.63; 95% CI = 1.04 to 2.54; P = 0.03 and OR = 1.59, 95% CI = 1.02 to 2.48; P = 0.04; respectively). We did not find association of these polymorphisms with nicotine dependence related scores. Polymorphisms in the CHRNA2, CHRNA3 and CHRNB3 genes were not associated with the phenotypes studied. Conclusion: CHRNA5 rs16969968 and rs2036527 were associated with higher success rate in the smoking cessation treatment in women. These findings might contribute to advances in personalized medicine.